Please Note:
This profile was automatically generated using 52 references found on the Internet. This information has not been verified. Learn more...
This profile was automatically generated using 52 references found on the Internet. This information has not been verified. Learn more...
View all 52 references Web References
-
1. Transgene
www.transgene.com/us/investor_ - [Cached]Published on: 7/3/2008 Last Visited: 7/3/2008
Mary Clark81, Whitfield Street London W1T 4HGTel : +44 (207) 307 5337
In France -
2. BioBusiness Workshop & Investor Network Series
www.investinbiotech.com/bio_wo - [Cached]Published on: 11/4/2004 Last Visited: 2/3/2008
Moderator: Mary Clark, Head of Life Sciences, Capital MS&L -
3. Capital Communications MS&L
www.capitalmsl.com/capital/our - [Cached]Published on: 1/26/2008 Last Visited: 1/26/2008
Mary Clark, Director
...
Mary Clark, Director
Mary heads up Capital's Life Sciences team.She specialises in building proactive communications programs for life sciences companies at all stages of development, ranging from pre-IPO initiatives to expanding the reach of established multinational corporations.Her clients include Teva Pharmaceutical, Jerini, Pharmexa, Intercell, Bavarian Nordic and Hunter-Fleming.
Mary was previously Head of the European Consulting team at Thomson Financial, the world's largest investor relations company, where she advised a large number of companies including on all aspects of financial communications.
Prior to Thomson Financial, she was Director of Corporate Communications at BTG plc.Whilst at BTG, she was involved in the Company's IPO on the LSE, various fund raisings, the demerger and listing on the LSE of its subsidiary Torotrak, and the starting up of several new biotech companies.During her time at BTG, Mary saw its market capitalisation rise from $60 million at IPO to over $2.5 billion.
Mary was ranked in the top 3 biotech professionals in Extel investor relations survey voted by leading institutional investors and sell-side analysts.
